Our chief editor Dr. Benjamin Pradere (FR) interviews Dr. Yohann Loriot (FR) on the phase 3 randomised THOR trial. This is a trial assessing erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor (FGFR) alterations.
